BACKGROUND: Follow-through of a positive screening test is necessary to reap the potential benefits of cancer screening.
Racial variation in follow-through diagnostic care may underlie a proportion of the known disparity in prostate cancer mortality. The authors used data from the screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial to determine whether race is associated with the use of follow-up diagnostic testing after a positive initial screening evaluation.
METHODS: Men who had a prostate-specific antigen (PSA) level >4 ng/mL at any time during the study were included. The proportion of men who underwent follow-up evaluation with a repeat PSA, a prostate biopsy, or either test within 9 months was determined, and the authors tested for differences in follow-through according to race using mixed-effects multivariate models with a random effect for accrual site to account for clustering. Models were stratified according to age (< 65 years and ≥65 years).
RESULTS: Among 6294 men who had a PSA elevation during the study period, 70% underwent a repeat PSA or prostate biopsy within 9 months. Non-Hispanic black men aged < 65 years had 45% lower odds of undergoing a repeat PSA test or prostate biopsy compared with non-Hispanic white men (odds ratio, 0.55; 95% confidence interval, 0.37-0.82), whereas there was no racial difference in follow-through among older men.
CONCLUSIONS: The current results suggest that limitations in access to care among non-Hispanic black men under the age of Medicare eligibility may underlie the paradoxically low use of follow-through diagnostic care among non-Hispanic black men in the United States.
Written by:
Barocas DA, Grubb R 3rd, Black A, Penson DF, Fowke JH, Andriole G, Crawford ED. Are you the author?
Department of Urologic Surgery, Vanderbilt University, Nashville, Tennessee; Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, Tennessee.
Reference: Cancer. 2013 Apr 4. Epub ahead of print.
doi: 10.1002/cncr.28042
PubMed Abstract
PMID: 23559420
UroToday.com Prostate Cancer Section
